Veru Presents Phase 2 and 3 Enobosarm Data At ADA Scientific Sessions: Well-Tolerated With Comparable Adverse Event Profile To Placebo; Effective In Reducing Fat And Preserving Lean Mass In Older Adults And Cancer Patients
Veru Presents Phase 2 and 3 Enobosarm Data At ADA Scientific Sessions: Well-Tolerated With Comparable Adverse Event Profile To Placebo; Effective In Reducing Fat And Preserving Lean Mass In Older Adults And Cancer Patients
Veru在ADA科學會議上介紹了2和3期Enobosarm數據:與安慰劑相比，耐受性好且不良事件剖面相似; 對老年人和癌症患者減少脂肪和保留瘦體有效
Veru Presents Phase 2 and 3 Enobosarm Data At ADA Scientific Sessions: Well-Tolerated With Comparable Adverse Event Profile To Placebo; Effective In Reducing Fat And Preserving Lean Mass In Older Adults And Cancer Patients
Veru在ADA科學會議上介紹了2和3期Enobosarm數據:與安慰劑相比，耐受性好且不良事件剖面相似; 對老年人和癌症患者減少脂肪和保留瘦體有效
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。